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The eosinophil granule major basic protein (MBP)  1 is an arginine rich, highly 
basic, 9,300 dalton protein, which forms the crystalloid core of the granule (1- 
3) and is present in small amounts in basophils (4).  MBP is toxic to parasites (5- 
7) and is  deposited onto  the surface of damaged microfiliariae in  Onchocerca 
volvulus infestation (8).  MBP is also toxic to cells (5, 9) and causes desquamation 
of respiratory epithelial cells in vitro (10,  11).  Finally, MBP triggers histamine 
release from human basophils and rat mast cells (12). 
We  have  recently reported  that  MBP  circulates in  the  blood  of pregnant 
women at levels 10 to 20 times those found in normal, nonpregnant women (13). 
The  levels  of this  immunoreactive MBP  increase  during  the  first  3  mo  of 
gestation, plateau during the second and third trimester, and decrease sharply 
following parturition.  Eosinophilia is not present during pregnancy, and other 
eosinophil-related proteins  are  not  elevated in  the sera of pregnant  women. 
Chromatographic  analysis  of sera  from  pregnant  women  indicates  that  the 
immunoreactive MBP has an apparent molecular size greater than the molecule 
purified from the eosinophil granule. These observations suggest that the im- 
munoreactive MBP molecule in the sera of pregnant women is derived from a 
source other than the eosinophil. Here we report that immunoreactive MBP is 
localized in placenta, intracellularly in placental X  cells and placental-site giant 
cells and extracellularly in anchoring villi and at the choriodecidual junction. 
Materials and Methods 
Tissue.  Placental tissue was prepared in the delivery suite for fixation and embedding. 
First  and second trimester medical  abortion tissues were kindly provided by Dr.  M. 
Hansen, Minneapolis,  MN. Other placental  and gestational  tissues were available from 
the Department of Pathology of the Mayo Clinic. Table I lists the types of tissues and the 
number of blocks examined from each. 
This work was supported by grants AI 15231, AI 09728, HL 07222 from the National Institutes of 
Health and a grant from the Mayo Foundation. Correspondence should be addressed to D. Maddox, 
Department of Immunology, Mayo Clinic, Rochester,  MN 55905. 
Abbreviations used in this paper:  MBP,  eosinophil granule major basic protein; PBS, phosphate- 
buffered saline; HE, hematoxylin and eosin. 
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TABLE  I 
Tissues Examined  for MBP by Immunofluorescence 
Num- 
Num-  ber of 
Clinical diagnosis  ber of  Tissue  blocks 
cases  exam- 
ined 
Normal gestation  14  Placenta  53 
Umbilical cord  6 
Membranes  3 
Tubal pregnancy  13  Fallopian tube with conceptus  17 
2  Concurrent endometrium  2 
Medical abortion  14  Placenta  14 
Spontaneous abortion  1  Placenta  3 
Hydatidiform mole  3  Uterine curettings  4 
Choriocarcinoma  2  Uterine curettings  4 
Miscellaneous*  37 
* This category includes placental tissues from single or few cases of severe pre- 
eclampsia, twins, pruritic urticarial plaques and papules of pregnancy (PUPPP) 
syndrome, fetal  anencephaly,  placenta  accreta,  placental  abruption,  and re- 
tained placenta; other tissues included endometriosis  (hysterectomy  specimen) 
and maternal skin. 
Immunofluorescence Localization of MBP.  The  indirect  immunofluorescence  method 
has been described in detail  (14-16).  Briefly,  formalin-fixed,  paraffin-embedded  tissue 
was sectioned at 6 #m and glued to glass microscope slides. Sections were deparaffinized, 
rehydrated,  and digested  with trypsin.  Tissues were washed and incubated  under  10% 
normal goat serum to inhibit nonspecific interactions between second stage reagents and 
the tissue. They were incubated with either affinity-purified rabbit anti-MBP antibody or 
protein A affinity-purified normal rabbit IgG as a control, followed by washing, treatment 
with chromotrope 2R to prevent nonspecific eosinophil fluorescence, repeat washing, and 
exposure  to the second stage goat anti-rabbit  Ig antibody conjugated with  fluorescein 
isothiocyanate. After a final wash, sections were sealed under coverslips, using a glycerol/ 
phosphate-buffered saline (PBS) (9:1) mounting medium made  10 mg/ml in para-phen- 
ylenediamine to inhibit fluorescence fading. Immunofluorescence microscopy used a Zeiss 
microscope fitted with Zeiss IV FL vertical illumination for epifluorescence and a fluores- 
cein filter system (Carl Zeiss, Inc., Thornwood, NY). In some instances, sections showing 
positive immunofluorescence were photographed, the coverslip was soaked off, the section 
was counterstained  with hematoxylin and eosin (HE), and areas of interest  were photo- 
graphed again to permit direct correlation between  fluorescent structures  and conven- 
tional histoiogic landmarks.  Photomicrography was carried out using Kodak Ektachrome 
400 ASA slide film (fluorescence) or Kodak Ektachrome 64 ASA slide film (HE counter- 
stains) in a  Zeiss M35 camera back mounted with power winder. The exposure time for 
fluorescence was 60 s. 
Giemsa Staining for Eosinophils.  Tissue  specimens  were  processed  as  described  by 
Godfrey et al.  (17) to determine  whether eosinophils were present  in placenta.  Briefly, 
fresh tissue  was reduced by sharp  dissection to 2-mm cubes,  immersed  in  Karnovsky's 
fixative (18) for 2 h at room temperature,  and incubated in the cold overnight in 0.2 M 
cacodylate buffer. Fixed tissue was embedded in methacrylate and 2-tzm sections were cut 
and mounted on glass slides.  Sections stained with Giemsa at pH 6.5 were examined by 
light microscopy. 
Extraction of MBPfrom Placental Tissue.  Placental extracts were obtained as summa- 
rized  in  Table  II.  Tissue  was  prepared  for extraction  by mincing  fresh  tissue  with  a 
scissors, until cubes of approximately 2-4 mm were obtained. To remove maternal blood, 
minced tissue  was washed on stainless steel  sieves (U.  S.  Standard  mesh No.  100) with 
cold saline until the effluent was clear. After weighing, tissue was homogenized in a glass- MADDOX  ET  AL. 
TABLE II 
Conditions for Extraction of  MBP  from Placental Tissue 
31 
MBP re-  Starting material  Pretreatment  Extraction solvent  covery* 
Fresh tissue  None  0.15 M NaCI  9,310 
Fresh tissue  (a)  0.1%  collagenase digestion at  0.15 M NaCI/0.01 M HCI  17,378 
37"C for 18 h in PBS and (b) 
reduction and alkylation* 
Freeze-thawed tissue  None  0.15 M NaCI  9,127 
Freeze-thawed tissue  None  0.15 M NaCI/0.01 M HCI  13,429 
Freeze-thawed tissue  Reduction  and alkylation in  0.4  0.4 M NaHBO,/NaH2BO4  14,797 
M  Na~HBO4/NaH2BO4 
* Recoveries are expressed as nanograms MBP per gram (wet weight) tissue, determined in the two- 
site immunoradiometric  assay. 
* Placental extracts  were  reduced in 0.0075  M dithiothreitol  and they were incubated  at room 
temperature for 60 rain. Extracts were alkylated with iodoacetamide, final concentration 0.015 M, 
and they  were  incubated  for 20  rain at room temperature. See reference  13  for a  complete 
discussion of the previously established  need for reduction  and alkylation in  immunochemical 
detection of MBP. 
glass Dounce instrument, using 100 strokes. In some instances, minced tissue fragments 
were digested with 0.1% collagenase in Dulbecco's PBS at 37°C for 18 h before homog- 
enization. Homogenates were centrifuged at 40,000 g for 1 h and the supernatants were 
analyzed for MBP by radioimmunoassay. 
In two instances, immediately after delivery, placental septal or chorionic plate cysts 
were  identified  and  subjected  to  needle  aspiration.  Cyst contents  were  serous,  straw- 
colored fluids. 
Radioimmunoassay of Tissue Extracts and Cyst Fluids.  The assays used for the determi- 
nation  of MBP  have been  described  in  detail  elsewhere  (13,  19).  A  double antibody 
inhibition assay (19) was used both for extracts and cyst fluids, and a two-site immunora- 
diometric assay (13) was used for extracts and for monitoring of column fractions resulting 
from gel permeation chromatography of extracts. 
Chromatography of Placental Extracts.  A  1.6  ×  50-cm  Sephadex  G-50  column  was 
equilibrated with 0.15 M NaCl, 0.01 M HCI at 4 o  C. Tissue extracts prepared as described 
in Table II were centrifuged at 40,000 g for 60 min, made 5-10% in sucrose, and applied 
to the column under the eluent. In experiments using placental extracts not reduced and 
aikylated during  tissue extraction,  the sample was reduced  and alkylated as described 
previously for pregnancy serum (13) before application to the column. Elution was carried 
out at a flow rate of 5 ml/cm  2 per hour and 2.7-ml fractions were collected. 
Results 
Localization  of Immunoreactive MBP by Immunofluorescence.  Fig.  1  shows  the 
typical  pattern  of  MBP  immunofluorescence  localization  in  term  placentae. 
Immunofluorescence staining was limited  to anchoring villi and  was present at 
both cellular and extracellular sites; no tissue elements of absorptive villi, includ- 
ing  syncytiotrophoblast,  cytotrophoblast,  Hofbauer  cells,  and  fetal  vasculature 
were stained. The cellular staining was confined to X  cells, the large round cells 
found in anchoring villus and placental floor but not in absorptive villi. Higher 
magnifications show  that  only certain  X  cells have intense,  diffuse cytoplasmic 
staining.  Some  X  cells are  less  intensely  stained,  showing  predominantly  peri- 
nuclear  speckling,  and  some  do  not  stain  at  all.  The  extracellular  substance 
showing such  intense fluorescence  is, when  viewed by transmitted  light in  HE- 
stained sections, a  palely eosinophilic,  ground  glass-appearing material,  clearly PLACENTAL  IMMUNOREACTIVE  MAJOR  BASIC  PROTEIN 
Fmtsgz  1,  lmmunofluorescence for  MBP in delivered normal placenta.  In this figure all 
panels are views of one tissue section, processed first for MBP immunofluorescenee, photo- 
graphed, and then counterstained with HE and again photographed. An exception to this is 
C, which is ~a section serial to that shown in the other panels, processed for immunoBuorescence 
using normal rabbit lgG (instead of rabbit anti-MBP antibody) as a negative control. A is a low 
power  view of placenta.  The small islands of tissue are  the absorptive villi (arrowheads), 
surrounded by the maternal blood space (b); in this section most of the blood has been washed 
out. The large central connective tissue structure (v) is an anchoring villus. B shows a higher 
magnification of the anchoring villus indicated by the box in A. The large round cells are X 
cells, the predominant cell type of the anchoring villus, and they are surrounded by a pale, 
ground glass-appearing substance. C is the serial section immunofluorescence-negative  control MADDOX  ET  AL.  33 
FIGURE 9.  Immunofluorescence  for MBP in delivered placenta. A and B show serial sections 
from a normal  placenta  in which the immunofluorescent  material of an anchoring  villus is 
extracellular  and  gathered into  a  small lake,  presumably  a  microscopic precursor to  the 
macroscopic placental septal cyst. A is stained with HE and B is stained for immunofluorescence. 
(A and B) X 100. 
distinguishable from maternal fibrinoid (20), which does not exhibit fluorescence. 
Fig. 2  shows the gathering of extracellular fluorescent material into a  small lake, 
surrounded  by palisades of X  cells. This appears to be the microscopic counter- 
part of the macroscopic placental septal cyst. 
Although affinity-purified antibody was used exclusively for the figures shown 
here,  our  initial  experiments,  which  gave  identical  results,  were  made  using 
whole rabbit antiserum  to  MBP.  Tests of the specificity of this antiserum  were 
carried out and the results are shown in Table III. Immunofluorescent staining 
of  placenta  was  not  altered  by  absorption  with  an  unrelated  basic  protein, 
protamine,  but  was  completely abolished  by absorption  with  MBP-Sepharose. 
Further, neither preimmunization sera obtained from the same rabbit nor serum 
of another  animal  immunized  with  complete  Freund's  adjuvant  alone  stained 
placenta. 
In  addition  to  these  immunochemical  tests  of  specificity,  we  determined 
whether  immunofluorescent  staining  of placenta  simply reflected  the  presence 
of maternal serum containing high levels of immunoreactive MBP. Maternal skin 
was resected at the time of cesarean  section and was tested for immunofluores- 
cence;  no  staining  was  found.  Similarly,  when  maternal  blood  was  clotted, 
formalin fixed, paraffin embedded, and stained for MBP, no staining was found 
except for the occasional brightly fluorescent peripheral blood eosinophil. 
To determine whether all anchoring villi stained,  sections cut from  17 blocks 
made from 8  normal placentae were examined.  Of 34 anchoring villi identified 
on  the  HE-stained  sections,  33  had  MBP  immunofluorescence  (>97%).  The 
showing the same field as that shown in B and D. Panel D (the same field as B) shows that 
fluorescence is restricted to the anchoring villus; no elements of the absorptive villi at the left 
of the panel show fluorescence. Note that absorptive villi do not contain X cells. Comparison 
of  D with B shows that although fluorescence is predominantly extracellular, some cytoplasmic 
staining is present as well. E and F (identical fields) show a higher magnification of the central 
area of D and demonstrate that only certain  X cells have cytoplasmic fluorescence  (open 
arrows). There are no distinguishing characteristics on HE staining that permit prediction of 
which X cells will have fluorescence. G and H are higher magnification views of another area 
of the same tissue section, beyond  the field of view shown in A. G and H (identical fields), 
when compared with E and F, show the two patterns of cytoplasmic immunofluorescence, 
diffuse staining and perinuclear speckling. A, B, E, and G are stained with HE; C, D, F, and H 
are processed for immunofluorescence. (.4) x 25, (B-D)  × 100, (E-H) × 400. 34  PLACENTAL  IMMUNOREACTIVE  MAJOR BASIC PROTEIN 
TABLE III 
Immunochemical Specificity of lmmunofluorescence 
Fluores- 
Reagent  Adsorbent*  cence re- 
suits 
(a) Rabbit antihuman MBP antiserum  None  + 
Protamine-Sepharose*  + 
MBP-Sepharose 
(b) Normal rabbit serum (preimmune  None 
serum)  i 
(c)  Normal rabbit serum 
(d) Serum of rabbit treated with com- 





* The preparation of these adsorbents is described in reference 15. 
* Protamine was selected as a cationic protein  with physicochemical qualities 
similar to those of MBP; macromolecular interactions based on charge rather 
than  immunologic specificity would likely affect MBP and  protamine  to a 
similar extent. 
J This was preimmunization serum obtained from the same animal from which 
the postimmunization specific  antiserum tested in a was obtained. 
presence or absence of uterine labor had no effect on fluorescence, inasmuch as 
placentae  obtained  by  elective  cesarean  section  were  indistinguishable  from 
placentae delivered spontaneously. 
Because initial immunofluorescence observations were made on third trimes- 
ter-delivered  placentae,  we  investigated  placental  MBP  immunofluorescence 
during  earlier  stages  of gestation.  All  14  placentae  examined  from  first  and 
second trimester terminations of pregnancy (7 from each trimester) and a  6-wk 
spontaneous  abortion  showed  both cytoplasmic and  extracellular  MBP  immu- 
nofluorescence comparable to that shown in Figs.  1 and 2; the earliest placentae 
studied were obtained at 6 wk gestation. 
The above results indicate that placental anchoring villi and certain of the X 
cells  therein  stain  for  MBP  by  immunofluorescence.  Fig.  3  shows  sections 
obtained  from a  postpartum  hysterectomy where  placental  bed  and  decidual 
structures were found isolated by myometrium but in close proximity. The areas 
of deep adenomyosis contained only maternal  decidual cells and did not stain, 
while the areas at the placental insertion site, containing X  cells and placental- 
site  giant  cells,  stained  brightly.  This  observation  was  confirmed  in  another 
specimen  by comparison  of biopsies  of decidua  vera  (endometrium  from  the 
uterine wall opposite the placental insertion site) and decidua basalis  (endome- 
trium at the placental insertion site).  The decidua vera did not stain while the 
decidua basalis was strongly positive. These results suggest that MBP immuno- 
fluorescence is limited to trophoblastic and not maternal cellular elements at the 
choriodecidual junction. 
Additional  evidence favoring a  trophoblastic  origin  for the  immunofluores- 
cence-containing cells was  obtained from examinations of tissues  from ectopic 
tubal gestations. Cellular immunofluorescence was observed in the conceptus of 
10 of 13  tubal  gestations,  with some extracellular fluorescence in  2  of the  10 
positive specimens. Hysterectomy was performed at the time of resection of two 
of the tubal gestations and the uterine decidual endometrial tissue had no MBP 
immunofluorescence,  while  the  tubal  conceptus,  with  no surrounding  uterine FIGURE 3.  Immunofluorescence  for  MBP  in  a  postpartum  hysterectomy  specimen.  The 
patient from whom this tissue was obtained underwent a cornual resection for tubal gestation 
in the past. The present gestation was complicated by uterine atony in the third stage of labor, 
necessitating  hysterectomy.  All  panels  are  views of one  tissue  section,  processed  first  for 
immunofluorescence and subsequently counterstained with HE. A is a low power view showing 
endometrial epithelial cells and stroma implanted deep in myometrium (deep adenomyosis) as 
a consequence of the previous cornual resection. The endometrial elements have undergone 
the decidual changes of gestation. B is a higher magnification of the central area in A. C shows 
the complete absence of immunofluorescence in the identical field of deep adenomyosis framed 
in B. Panel D shows an area of the placental insertion site, at some distance from the area of 
deep  adenomyosis.  E  and  F  (identical  fields) show  a  higher  magnification  of the  striking 
cytoplasmic immunofluorescence of the binucleate placental-site giant cells,  located near the 
center of D. G and H (identical fields) are higher magnifications of the placental insertion site 
beyond  the  field of view in  D  and  show  that  placental-site  giant  cells are  associated  with 
extracellular immunofluorescence. (A) x  25, (B-D) X 100, (E-H) x  400. 
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decidual cells, was positive for MBP immunofluorescence in both cases. 
Placentae from single cases of retained placenta, placental abruption, placenta 
accreta, and two cases of the pruritic urticarial plaques and papules of pregnancy 
syndrome all demonstrated specific immunofluorescence. Endometrial curettings 
from one case of chorioadenoma and three cases of hydatidiform mole showed 
cytoplasmic and extracellular fluorescence. One biopsy specimen of choriocar- 
cinoma showed minimal cytoplasmic fluorescence and a  second specimen had 
none. Endometrium from two premenopausal nongestational hysterectomy spec- 
imens, placenta from one case of anencephalic fetus, a  normal fallopian tube, 
and a normal uterine cervix were all negative for specific immunofluorescence. 
Finally, umbilical cord did not show immunofluorescence. Examination of 20 
methacrylate-embedded, Giemsa-stained sections of normal term placental tissue 
revealed no eosinophils other than the occasional typical peripheral blood eosin- 
ophil in a vascular space. 
MBP in Tissue Extracts and Cyst Fluids.  Because of the prevalence and intensity 
of the placental immunofluorescence findings, we attempted to solubilize placen- 
tal  MBP  for  comparison  with  MBP  previously purified  from  the  eosinophil 
granule. Dose-response curves for placental extract and purified MBP tested in 
the  two-site immunoradiometric assay are shown  in  Fig.  4a.  The  curves are 
superimposable down to  very low concentrations, where the placental extract 
shows greater anti-MBP antibody-binding activity. The dose-response curves for 
all five placental extracts shown in Table II were not statistically different from 
each other or the  MBP  standard,  regardless of the extraction protocol  used. 
Table  II  shows  that  the  highest  yield  of MBP  from  placenta  resulted  from 
collagenase digestion, reduction and alkylation, and acidification. 
Fig. 4 b shows dose-response curves for purified MBP and placental cyst fluid 
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Comparison of immunochemical reactivity of eosinophil granule MBP with ma- 
terial derived from placenta. Points plotted in a and b are arithmetic means of assay duplicates; 
duplicates  did  not  vary  >4%.  (a)  Dose-response  curves  for  eosinophil  granule  MBP  and 
placental extract in the two-site immunoradiometric assay.  Placental extract No. 4 (see Table 
II) was tested here. Extracts prepared by any of the protocols in Table II gave dose-response 
curves that did not differ. (0) Granule MBP, (A) placental extract.  (b) Dose-response curves 
for  granule  MBP  and  placental  cyst  fluid  in  the  double  antibody  radioimmunoassay.  (0) 
Granule  MBP,  (A) cyst fluid. Analysis of logit-log-transformed data revealed coefficients of 
determination  for  the  MBP  and  cyst  fluid  regressions  were  0.98  and  0.99,  respectively. 
Though very similar, slopes for these lines were statistically different (F],as -- 4.9; 0.05 >  P > 
0.01 ) by a one-way analysis of covariance. MADDOX  ET  AL.  37 
as determined in the double antibody inhibition assay for MBP. From this assay, 
cyst  fluid  contained  100  gg  MBP/ml,  a  sixfold  increase  above  the  highest 
maternal  serum  levels  measured  in  gestation.  When  placental  extracts  were 
subjected  to  gel  permeation  chromatography on  Sephadex  G-50,  all  of the 
immunoreactivity was associated with the void volume species, as has been shown 
for the serum MBP molecule of gestation (13). 
Discussion 
The isolation of major basic protein from the eosinophil granule, its physico- 
chemical properties,  and  its  biological  activities  have  been  reviewed (3,  21). 
Human MBP is a relatively small arginine-rich protein, which in solution behaves 
as a polycation having an isoelectric point >10.  MBP has at least two solvated 
sulfhydryl groups and it readily self-associates in concentrated solutions to form 
polymeric molecules. MBP  is  largely protein bound in physiological fluids, on 
the basis of both charge and disulfide linkages. When MBP is polymerized or 
covalently bound to other proteins, its recognition by a variety of specific antisera 
is inhibited (6,  19);  for this reason, quantitative immunochemical measurement 
requires prior reduction and alkylation under nondenaturing conditions. 
In the guinea pig,  MBP is the sole constituent of the crystalloid core of the 
eosinophil granule (22).  Human MBP is elevated in the serum of patients with 
eosinophilia,  and  the  degree  of  elevation  is  correlated  with  the  degree  of 
eosinophilia (19) and with elevation of other eosinophil-related proteins such as 
Charcot-Leyden crystal protein (23). MBP is found in high concentrations in the 
sputum of patients with bronchial asthma (11) and has been demonstrated by 
immunofluorescence in the mucus plugs obstructing the bronchi of patients who 
have died with asthma (15).  MBP provokes histamine release from basophils in 
a specific, noncytotoxic manner (12), but it is directly toxic to tracheal epithelium, 
other mammalian cells, and several helminths (3, 21). MBP has, therefore, been 
postulated as a  mediator of the bronchial epithelial damage in asthma and of 
eosinophil-directed helminthocidai immune responses. 
We have recently discovered that serum levels of immunoreactive MBP are 
elevated throughout human pregnancy (13). The degree of elevation correlates 
with the stage of gestation,  with levels increasing from pre-gravid normals of 
<600  ng/ml to a  plateau of ~7,500  ng/ml by the 20th wk of gestation.  This 
elevation is comparable to the elevation of MBP seen in the serum of patients 
who  have  extreme degrees  of peripheral  blood  eosinophilia,  such  as  in  the 
hypereosinophilic syndrome (19). Because cord serum MBP levels were normal, 
because maternal serum levels began to fall after delivery, and because we were 
unable to show any peripheral blood eosinophilia or elevation of other eosinophil- 
related proteins  in  serum of pregnant  women with  elevated serum  levels of 
immunoreactive MBP,  we  postulated  that  the  placenta  is  the  source  of this 
molecule.  Here  we  show  that  immunoreactive  MBP  is  localized  in  human 
placental tissue.  The MBP localization is immunochemically specific, as shown 
by absorption experiments, and anatomically specific, as shown by its presence 
only in  association  with placental X  cells and placental-site giant cells and its 
absence  in  maternal  blood  clot  and  nonreproductive  maternal  tissues.  The 
cytotrophoblast and  syncytiotrophoblast,  which are  the  predominant  cellular 
elements in placenta, are not associated with MBP immunofluorescence. It seems 38  PLACENTAL  IMMUNOREACTIVE MAJOR BASIC PROTEIN 
unlikely that maternal endometrial deciduai cells contribute to placental MBP 
immunofluorescence, because staining is seen in ectopic tubal pregnancy tissue 
where there are no maternal decidual cells present. Similarly, as shown in Fig. 
3, the maternal decidual cells in the areas of deep adenomyosis, removed from 
the placental insertion site, are not associated with MBP immunofluorescence, 
while the adjacent areas from the same specimen, at the placental insertion site, 
stain positively for MBP in and around the placental-site giant cells. 
MBP immunofluorescence  appears to be present throughout normal gestation, 
because we found specific staining in placental tissue from terminations of normal 
gestation as early as 6 wk after conception. Although some specimens from early 
gestation had extracellular staining as well as cytoplasmic staining of X cells and 
placental-site giant cells,  in  general,  the earlier the gestation the more likely 
cytoplasmic  fluorescence  predominated  over  extracellular  fluorescence.  The 
presence  of MBP  immunofluorescence was  unaffected by  the  occurrence of 
uterine labor;  placental specimens obtained by elective cesarean section were 
indistinguishable from those delivered after spontaneous parturition.  This was 
also  true  when  tissues  from  terminations  of pregnancy  (vacuum  extraction 
without hormonal or pharmacologic interventions) were compared with tissues 
from spontaneous abortion. 
We used the method of Godfrey et al. (17) to search for placental eosinophiis 
because it offers two advantages over conventional histologic methods. Sections 
are thin enough to permit enumeration of single cells, and the tinctorial prop- 
erties of mast cells, basophils, neutrophils, and eosinophils are the same as those 
usually obtained  in  peripheral blood,  allowing unambiguous identification. In 
spite of these optimal conditions for observation, we were unable to demonstrate 
any tissue eosinophils in placental tissue in which abundant MBP immunofluo- 
rescence was found. 
Quantitation of immunoreactive MBP in extracts of human placenta by both 
radioimmunoassay and immunoradiometric assay offers confirmatory evidence 
for  the  immunofluorescence findings.  The  observation  that  immunoreactive 
MBP concentrations in placental cyst fluid are more than six times higher than 
the  highest  levels  measured in  maternal  serum discourages  belief that  MBP 
extracted from placenta is due solely to the content of maternal blood in the 
tissue.  Localization of these very high concentrations of MBP to the placental 
cysts might be expected on the basis of our histologic and immunofluorescence 
finding and because prior observations have established the association of pla- 
cental cysts with placental X  cells, which are found lining the inner aspects of 
the cysts (24). 
The limited physicochemical data available for the MBP molecule in placenta 
and maternal serum suggest some differences in comparison with MBP isolated 
from the eosinophil  granule.  In  the  immunoradiometric assay,  dose-response 
curves for placental extracts and granule MBP are superimposable over most of 
the working range of the assay,  except at  very low concentrations where the 
placental extract actually has greater anti-MBP antibody binding activity than 
granule MBP. In the double antibody inhibition assay used to compare cyst fluid 
with purified granule MBP, cyst fluid MBP completely displaced granule MBP 
from specific antibody and the slope of the dose-response curve for cyst fluid 
MBP was greater than that for granule MBP. Finally, as has been shown for the MADDOX ET  AL.  39 
MBP in maternal serum (13), the MBP in placental extracts appears at the void 
volume of a  Sephadex G-50 column instead of at the expected elution volume 
for monomer MBP isolated from the eosinophil granule. This latter observation 
suggests that the placental MBP molecule is larger than the eosinophil granule 
monomer MBP, and it is reasonable to speculate that the failure of perfect slope 
concordance in dose-response studies is somehow related to this apparent molec- 
ular size difference. 
The 0recise origin of placental X  cells and placental-site giant cells is contro- 
versial and their function is unknown. Placental X  cells were first described by 
Scipiades and Burg (25), who noted their consistent location in placental septae, 
lining cystic structures, and in the basal decidual floor, where they are usually 
enmeshed in maternal flbrinoid, scattered among maternal decidual cells. Ultra- 
structural studies have shown that these cells possess a microvillus surface, well- 
developed Golgi apparatus,  and  extensive rough endoplasmic reticulum,  sug- 
gesting  very  active  protein  biosynthetic  activity  (26).  Autoradiography  using 
tritiated thymidine has revealed DNA synthesis in a substantial portion of these 
cells (24), and immunofluorescence examinations for human chorionic gonado- 
trophin have been negative (27). An association between severe abnormal prolif- 
eration of X  cells and fetal intrauterine growth retardation has been reported 
(28). In contrast, much less is known about the placental-site giant cell. This cell 
is found only in relation to maternal  endometrial and myometrial cells at the 
placental  insertion site.  Immunofluorescence for human chorionic gonadotro- 
phin in these cells has been reported positive and, using quinacrine fluorescence 
(for F bodies) in male gestations, a  trophoblastic origin for placental-site giant 
cells has been reported (27). 
The immunofluorescence findings in this paper provide some immunochemical 
evidence to  suggest that  the  X  cells  and  the  placental-site  giant  cell  may be 
functionally related specialized derivatives of trophoblast. The placental-site giant 
cell has been postulated to play a key role in establishing the invasiveness of the 
trophoblastic mass at the time of implantation, and it is tempting to speculate 
that  MBP,  a  cytotoxic  molecule  as  isolated  from  the  eosinophil,  might  be 
synthesized by such an invasive cell to mediate maternal decidual cell necrosis 
and enhance implantation. This hypothesis fails to account for continued pro- 
duction  of MBP  throughout  gestation,  however,  and  leaves  unaddressed  the 
function of MBP produced by the placental X cell. 
Summary 
We have recently reported that human pregnancy is characterized by a  10- to 
20-fold elevation of eosinophil major basic protein (MBP) immunoreactivity in 
maternal  blood.  Here  we show,  by  immunofluorescence, that  placental  tissue 
specifically  binds  antibody  to  MBP  in  and  around  the  placental  X  cells  and 
placental-site  giant  cells and,  using thin  plastic  sections,  that  placenta  has  no 
infiltrating eosinophils. The X cells line the inner aspects of placental septal cysts, 
and  the  cyst  fluid,  obtained  by  aspiration,  contains  immunoreactive  MBP  at 
concentrations of 100 #g/ml, a  sixfold greater concentration  than the highest 
levels measured in maternal blood. 
The soluble MBP immunoreactivities in placental homogenates and in mater- 
nal serum chromatograph identically on Sephadex G-50, and both these gesta- 40  PLACENTAL IMMUNOREACTIVE MAJOR BASIC PROTEIN 
tional MBP molecules migrate as though substantially larger than the MBP found 
in serum from patients with hypereosinophilic syndrome or purified from the 
eosinophil granule. Our inability to demonstrate eosinophils in maternal blood 
or placental  tissue, coupled with the large quantities of immunoreactive MBP 
highly  localized  in  placental  cysts and  the  chromatographic  behavior  of this 
molecule,  suggest  that  the  MBP detected  in  human gestation  is  produced  by 
placenta. 
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